Big Pharma Just Got an Offer It Can't Refuse

Eli Lilly is spreading $50 billion across multiple sites, including a $4.5 billion research and manufacturing hub in Lebanon, Indiana. Amgen expanded its Ohio plant to a $1.4 billion project in April, projecting 750 jobs.

It's like a reality show where pharma CEOs compete to build the biggest factory. And the prize is not paying a 100% tax on their own products.

Analysts Aren't Losing Sleep

Wall Street's reaction has been remarkably calm. BMO Capital Markets expects limited effects, noting that carve-outs protect small biotechs and that firms like Regeneron anticipate securing their own deals soon. Jefferies pointed out that existing agreements set precedents, making it straightforward for most companies to avoid the full tariff.

ING analyst Diederik Stadig argued that the tariffs are geopolitically motivated rather than economically significant, since the top pharmaceutical-exporting countries to the U.S. are already covered by trade agreements or company-level deals.

Not everyone is celebrating, though. BIO president John Crowley warned that tariffs raise costs, hinder manufacturing buildouts, and could delay treatments. The Brookings Institution questioned whether onshoring will actually happen at scale, or whether companies will pocket their exemptions and quietly slow-walk construction. There's also a sunset clause worth noting: these MFN pricing deals and manufacturing exemptions expire on January 20, 2029, the last day of Trump's current term.

So companies are making decade-long investment decisions based on a policy that has a three-year shelf life. That's a bit like signing a 30-year mortgage because your landlord promised not to raise rent until next Tuesday.

Meanwhile, the Deal Machine Kept Rolling

The tariff drama shared the spotlight with a hyperactive week in biotech M&A. Biogen grabbed Apellis Pharmaceuticals for approximately $5.6 billion, paying $41.00 per share in cash plus up to $4.00 per share in contingent value rights (bonus payments tied to sales milestones for Apellis's eye drug SYFOVRE). That price tag represented a roughly 140% premium to where Apellis closed the day before. Not a bad payday for shareholders who stuck around.

Appellis brings approved drugs across ophthalmology, immunology, and rare diseases, giving Biogen a meaningful pipeline outside its traditional neuroscience wheelhouse. The deal fits a broader pattern: companies are using M&A to backfill revenue they'll lose as key patents expire over the next few years.

The Biogen-Apellis deal wasn't an isolated event, either. Q1 2026 saw nearly $47 billion in total M&A spending across biopharma, with six companies announcing up to $25.5 billion in deals over just eight days in late March. Merck's $6.7 billion acquisition of Terns Pharmaceuticals and Eli Lilly's $6.3 billion purchase of Centessa Pharmaceuticals were among the headliners.

The Peptide Problem Nobody's Talking About

Buried beneath the tariff and M&A headlines is a quieter story about trust. The FDA has been cracking down on compounding pharmacies that sell cheaper versions of popular peptide drugs, particularly GLP-1 agonists like semaglutide (the active ingredient in Ozempic and Wegovy). These compounded versions filled a gap for patients who couldn't afford or access the brand-name products.

But the crackdown is having an unexpected side effect. As regulators push patients away from compounders and toward expensive branded drugs, some patients are rejecting established medicines altogether. They're turning to unregulated peptide clinics selling treatments like BPC-157, a peptide with enthusiastic online fans but no rigorous clinical proof behind it. The irony is thick: patients distrust Big Pharma's proven drugs while embracing unproven alternatives from providers with the same profit motive but none of the safety requirements.

This erosion of trust has roots in legitimate grievances (the opioid crisis being the most obvious). But it creates a strange dynamic where FDA enforcement designed to protect patients may actually push some of them toward riskier choices.

What It All Means

The 100% tariff is less a wrecking ball than a negotiating chip. The administration gets to claim it's lowering drug prices and bringing manufacturing home. Pharma companies get to avoid crippling tariffs by making investments they were probably considering anyway. And everyone gets a photo op.

But the real tension is in the details. Will these manufacturing commitments actually materialize, or will they evaporate after 2029? Can the M&A spree continue if pricing pressure tightens margins? And will patients caught between overpriced brand-name drugs and unregulated alternatives find any good options at all?

The biotech industry just entered a new era of policy-driven chess. The opening moves look cooperative. The endgame is anyone's guess.

The $100M Bet on a Cancer Drug That Knows Where to Aim

A stealthy oncology startup just burst onto the scene with $100 million and a platform that claims to solve one of cancer drug development's oldest problems. The investors backing Stipple Bio read like a who's who of biotech venture capital, but the company hasn't even named its target yet.